Table 6.
Neutralization of SARS-CoV-2 wild-type virus and variants by selected monoclonal antibodiesa
| Antibody | Epitope group | Neutralization (IC50 in ng/mL in pseudovirus assays) against SARS-CoV-2 variants | Referencesb | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wild-type | WT-D614G | Alpha (B.1.1.7) |
Beta (B.1.351) |
Gamma (P.1, B.1.1.28) |
Delta b (B.1.617.2) |
Epsilon (B.1.427/B.1.429) |
Omicron (B.1.1.529.1; BA.1) b |
|||
| Bamlanivimab (LY3819253; LY-CoV555) | RBD-2 | 6–12 | 3–5 | 4–9 | > 10,000c | > 10,000 | 8311–> 10,000 | > 10,000 | > 10,000 | [80, 386, 391, 405] |
| Etesevimab (LY-CoV016, CB6) | RBD-1 | 26–35 | 31–52 | 22–3225 | > 10,000 | > 10,000 | 12–15 | 23–54 | 7600 – > 10,000 | [386, 391, 405] |
| Bamlanivimab plus Etesevimab | RBD-2/RBD-1 | ND | 9 | 11 | > 10,000 | > 10,000 | ND | 63 | > 10,000 | [391] |
| Casirivimab (REGN10933) | RBD-2 | 4–43 | 5–7 | 7–13 | 3284–> 10,000 | 1046–6177 | 3–7 | 4–9 | > 10,000 | [80, 386, 391, 405] |
| Imdevimab (REGN10987) | RBD-5A | 32–71 | 12–20 | 7–28 | 4–24 | 4–13 | 17–455 | 75–114 | > 10,000 | [80, 386, 391, 405] |
| REGEN-COV™ (Casirivimab plus Imdevimab) | RBD-2/RBD-5A | ND | 5 | 3 | 8 | 7 | 5 | 4 | > 10,000 | [80, 386, 391] |
| Cilgavimab (AZD1061; COV2-2130) | RBD-4 | 2–13 | 2–26 | 1–12 | 3–19 | 2–14 | 4–80 | 55 | 2178–5850 | [80, 386, 391, 405–407] |
|
Tixagevimab (AZD8895; COV2-2196) |
RBD-2 | 1–5 | 1–4 | 2–11 | 4–46 | 2–46 | 2–3 | 11 | 270–1150 | [80, 386, 391, 405–407] |
| Cilgavimab plus Tixagevimab | RBD-4/RBD-2 | 9 | 4 | 4–7 | 11–12 | 6–7 | ND | 5 | 51–418 | [80, 386, 405] |
|
Bebtelovimab (LY-CoV1404) |
RBD-5A | 3 | 3 | 2–31 | 2–4 | 1–12 | ND | 1–4 | 5 | [214, 405] |
| Amubarvimab (BRII-196) | RBD-1 | 30 | 53 | 31 | 30 | 41 | 42 | ND | 7258 | [407] |
| Romlusevimab (BRII-198) | RBD-5B | ND | ~ 180 | ~ 45–70 | ~ 580 | ~ 320 | ~ 1600 | ~ 430 | 82 | [382, 408] |
| ABBV-2B04 | UNK | ND | 1 | 1 | > 10,000 | > 10,000 | ND | 3 | ND | [386] |
| ABBV-47D11 | RBD-5B | ND | 319 | 305 | 240 | 277 | ND | 456 | ND | [386] |
| ABBV-2B04 plus 47D11 |
UNK/ RBD-5B |
ND | 3 | 2 | 431 | 384 | ND | 4 | ND | [386] |
| BMS C144 | RBD-2 | ND | 4–5 | 6 | > 10,000 | > 10,000 | 5 | ND | > 10,000 | [405] |
| BMS C135 | RBD-5B | ND | 11–17 | 14 | 34 | 15 | 25 | ND | 5850 | [405] |
| SARS2-38 | Likely RBD-5A | 2 | 2 | 3 | 4 | 2 | 4 | 1 | ND | [409] |
|
Sotrovimab (GSK4182136, VIR-7831) |
RBD-5B | 100 | 58 | 80 | 50 | 66 | 42 | ND | 180–340 | [80, 407] |
| S309 (precursor to Sotrovimab) | RBD-5B | 40 | 156 | 78–209 | 82–98 | 76 | 113 | 20 | 256–281 | [80, 386, 405] |
| B1-182.1 | RBD-2 | 3 | 1 | <1 | 1 | <1 | 2 | 2 | 281 | [391, 405] |
| S2E12 | RBD-2 | 2 | 5 | 21 | 10 | 2 | 2 | 2 | 38 | [386, 405] |
| S309/S2E12 combined | RBD-5B/RBD-2 | –– | 7 | 8 | 15 | 3 | ND | 5 | ND | [386] |
| IGM-6268 (as an IgM) | RBD-2 | 6 | ND | 31 | 31 | 23 | ND | ND | 230 | [245, 410] |
| Regkirona (Regdanvimab; CT-P59) | RBD-2 | <1–10 | 2–10 | 2–6 | 66–330 | 13–40 | 15–1,237 | 366 | > 10,000 | [405, 406, 411, 412] |
| ADG20 | RBD-5Ad | 1–4 | 5 | 2–6 | 5–16 | 3–9 | 1–8 | 1 | 1100–2037 | [80, 220, 405] |
| MW05 | RBD-4 | 30 | ND | Ca. 100 | > 10,000 | > 10,000 | ND | ND | ND | [316] |
| MW06 | RBD-4 | 250–340 | ND | Ca. 300 | Ca. 500 | Ca. 500 | ND | ND | ND | [316] |
| S2X259 | RBD-6 | 74–213 | ND | 205 | 358 | 458 | 101 | ~ 220 | 588 | [262, 406] |
| DZIF-10ce | UNK | 10 (LV) | ND | 14 (LV) | 170 (LV) | ND | ND | ND | ND | [227] |
| MAD0004J08 | UNK | 4 | 4 | 4 | ND | ND | ND | ND | ND | [221] |
| CAB-B37 | RBD-1 | ND | 63 | 46 | 25 | 34 | 82 | ND | 20 | [413] |
ND no data, RBD receptor-binding domain, UNK unknown, LV authentic live virus assay instead of pseudovirus assay
aAll numbers converted to nearest integer, and where multiple data were available, ranges spanning those data are given. These numbers are from many different experiments, protocols, laboratories, and using different wild-type comparators (different wild-type viruses and sometimes D614G was used as control/comparator), so the specific numbers may not be exactly comparable. Nevertheless, they represent the overall trends of potency which are critical to neutralization of the variants
bSome of the data on Delta neutralization are from Mlcochova et al. [58]; Data for Omicron (BA.1 only) are from: Dejnirattisai et al. [80]; Iketani et al. [109] (ng/mL values extrapolated from fold increase/decrease based on D614G data provided by other authors, Zhou et al. [405] and Cameroni [406]; Brii-198 actual neutralization figures in ng/mL have not been given, but figures of neutralization curves were provided, so the data presented here were extrapolated from figures shown by Wang et al. [382] and Liu et al. [408]
cPartial loss of activity (ca. 500–8000 ng/mL) in italics; essentially complete loss is noted by > 10,000 in bold; d Presumed based on description and figure of epitope [220], but not confirmed due to absence of detailed epitope mapping data
eDiscontinued from development 7/25/21